Swiss National Bank Coherus Bio Sciences, Inc. Transaction History

Swiss National Bank

$150 Billion
Q3 2024

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 06, 2024	SELL	$1.59 - $3.85 $20,829 - $50,435	-13,100 Reduced 6.26%	196,000 $652,000
Q3 2023 Nov 08, 2023	BUY	$3.74 - $5.45 $111,452 - $162,410	29,800 Added 16.62%	209,100 $782,000
Q2 2023 Aug 09, 2023	BUY	$3.79 - $8.3 $170,550 - $373,500	45,000 Added 33.51%	179,300 $765,000
Q1 2023 May 10, 2023	SELL	$5.89 - $10.52 $93,651 - $167,268	-15,900 Reduced 10.59%	134,300 $918,000
Q4 2022 Feb 08, 2023	BUY	$5.69 - $10.07 $18,777 - $33,231	3,300 Added 2.25%	150,200 $1.19 Million
Q3 2022 Nov 09, 2022	BUY	$7.17 - $13.87 $12,189 - $23,579	1,700 Added 1.17%	146,900 $1.41 Million
Q1 2022 May 09, 2022	BUY	$10.92 - $16.41 $123,396 - $185,433	11,300 Added 8.44%	145,200 $1.88 Million
Q3 2021 Nov 08, 2021	BUY	$12.68 - $17.79 $69,740 - $97,845	5,500 Added 4.28%	133,900 $2.15 Million
Q2 2021 Aug 06, 2021	SELL	$12.95 - $15.41 $42,735 - $50,853	-3,300 Reduced 2.51%	128,400 $1.78 Million
Q1 2021 May 07, 2021	BUY	$14.42 - $21.39 $44,702 - $66,309	3,100 Added 2.41%	131,700 $1.92 Million
Q3 2020 Nov 09, 2020	BUY	$17.41 - $19.89 $59,194 - $67,626	3,400 Added 2.72%	128,600 $2.36 Million
Q2 2020 Aug 05, 2020	BUY	$14.43 - $19.16 $334,776 - $444,512	23,200 Added 22.75%	125,200 $2.24 Million
Q1 2020 May 08, 2020	BUY	$11.67 - $22.53 $22,173 - $42,807	1,900 Added 1.9%	102,000 $1.65 Million
Q4 2019 Feb 06, 2020	BUY	$16.33 - $21.37 $39,191 - $51,288	2,400 Added 2.46%	100,100 $1.8 Million
Q3 2019 Nov 12, 2019	BUY	$16.3 - $23.37 $45,640 - $65,436	2,800 Added 2.95%	97,700 $1.98 Million
Q2 2019 Aug 02, 2019	BUY	$13.1 - $22.1 $187,330 - $316,030	14,300 Added 17.74%	94,900 $2.1 Million
Q1 2019 May 10, 2019	BUY	$8.38 - $15.5 $21,788 - $40,300	2,600 Added 3.33%	80,600 $1.1 Million
Q4 2018 Feb 13, 2019	BUY	$8.65 - $16.28 $33,735 - $63,492	3,900 Added 5.26%	78,000 $706,000
Q3 2018 Nov 08, 2018	BUY	$14.45 - $20.25 $52,020 - $72,900	3,600 Added 5.11%	74,100 $1.22 Million
Q2 2018 Aug 09, 2018	BUY	$10.25 - $17.45 $51,250 - $87,250	5,000 Added 7.63%	70,500 $987,000
Q1 2018 May 04, 2018	BUY	$9.1 - $13.7 $70,980 - $106,860	7,800 Added 13.52%	65,500 $724,000
Q4 2017 Feb 07, 2018	BUY	$8.35 - $14.4 $45,925 - $79,200	5,500 Added 10.54%	57,700 $508,000
Q3 2017 Nov 03, 2017	BUY	$11.1 - $14.5 $579,420 - $756,900	52,200	52,200 $697,000

Others Institutions Holding CHRS

# of Institutions

135

Shares Held

77.9M

Call Options Held

40.7K

Put Options Held

50.1K

Black Rock Inc. New York, NY

11.8M
Shares

$18.5 Million
0.0% of portfolio
Vanguard Group Inc Valley Forge, PA

11.3M
Shares

$17.8 Million
0.0% of portfolio
Rubric Capital Management LP New York, NY

10.4M
Shares

$16.3 Million
0.3% of portfolio
Kohlberg Kravis Roberts & Co. L.P. New York, NY

3.04M
Shares

$4.77 Million
0.18% of portfolio
Ken Griffin Citadel Advisors LLC | Chicago, Il

2.86M
Shares

$4.49 Million
0.0% of portfolio

View Full List

About Coherus BioSciences, Inc.

Ticker CHRS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,724,600
Market Cap $122M
Description
Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. T...

More about CHRS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Swiss National Bank, based on Form 13F filings with the SEC.

News

Stay updated on Swiss National Bank with notifications on news.

Account